OncoGenex to Present at Credit Suisse Healthcare Investor Conference

OncoGenex to Present at Credit Suisse Healthcare Investor Conference 
BOTHELL, Wash. and VANCOUVER, British Columbia, Nov. 5, 2013 /CNW/ - OncoGenex 
Pharmaceuticals, Inc. (NASDAQ: OGXI) announced today that Scott Cormack, 
President and Chief Executive Officer, will provide a corporate presentation 
at the Credit Suisse Healthcare Conference on Tuesday, November 12, 2013 at 
8:30 a.m. MST at the Phoenician Hotel in Scottsdale, Arizona. 
A live audio webcast can be accessed through the Investor Relations page of 
the OncoGenex website at www.oncogenex.com. The webcast replay will be 
archived for 60 days. 
Highlights from the presentation can be followed on the new OncoGenex Investor 
Relations Twitter account at: http://twitter.com/@OncoGenex_IR. 
ABOUT ONCOGENEX OncoGenex is a biopharmaceutical company committed to the 
development and commercialization of new therapies that address treatment 
resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with 
each product candidate having a distinct mechanism of action and representing 
a unique opportunity for cancer drug development. OncoGenex and Teva 
Pharmaceutical Industries Ltd. have entered a global collaboration and license 
agreement to develop and commercialize OncoGenex' lead drug candidate, 
custirsen. Custirsen is currently in Phase 3 clinical development as a 
treatment in men with metastatic castrate-resistant prostate cancer and in 
patients with advanced, unresectable non-small cell lung cancer. Apatorsen is 
in Phase 2 clinical development and OGX-225 is currently in pre-clinical 
development. More information is available at www.OncoGenex.com.
 

SOURCE  OncoGenex Pharmaceuticals, Inc. 
Media Contact: Jaime Welch, jwelch@oncogenex.com, 604-630-5403 or Investor 
Relations Contact: Susan Specht, sspecht@oncogenex.com, 425-686-1535 
http://www.OncoGenex.com 
To view this news release in HTML formatting, please use the following URL: 
http://www.newswire.ca/en/releases/archive/November2013/05/c4162.html 
CO: OncoGenex Pharmaceuticals, Inc.
ST: British Columbia
NI: HEA MTC BTC CONF SHOW  
-0- Nov/05/2013 11:30 GMT